Information Provided By:
Fly News Breaks for October 5, 2018
NBIX
Oct 5, 2018 | 06:12 EDT
After conducting a survey of 25 psychiatrists who manage pediatric patients with Tourette syndrome, Piper Jaffray analyst David Amsellem has heightened confidence that Neurocrine Biosciences' Ingrezza will have a significant role in the treatment landscape. To the extent that there is a label expansion in Tourette's, the product is likely to be seen as a more attractive dopaminergic-based agent relative to atypical antipsychotics, Amsellem tells investors in a research note. The analyst continues to believe that the upside potential for Neurocrine shares associated with favorable results in Tourette's is "significantly larger than the downside risk associated with a clinical setback." He reiterates an Overweight rating on the shares with a $115 price target.